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ABSTRACT
Background: Chemoresistance often limits the success of the pharmacological 
treatment in acute myeloid leukemia (AML) patients. Although positive results have 
been obtained with tyrosine kinase inhibitors (TKIs), such as sorafenib, especially 
in patients with Fms-like tyrosine kinase 3 (FLT3)-positive AML, the success of 
chemotherapy is very heterogeneous. Here we have investigated in vitro whether 
the transportome (set of expressed plasma membrane transporters) is involved in 
the differential response of AML to sorafenib.
Methods: The sensitivity to sorafenib-induced cell death (MTT test and anexin 
V/7-AAD method) was evaluated in five different cell lines: MOLM-13, OCI-AML2, 
HL-60, HEL and K-562. The transportome was characterized by measuring mRNA 
using RT-qPCR. Drug uptake/efflux was determined by flow cytometry using specific 
substrates and inhibitors.
Results: The cytostatic response to sorafenib was: MOLM-13>>OCI-AML2>HL-
60>HEL≈K-562. Regarding efflux pumps, MDR1 was highly expressed in HEL>K-
562≈MOLM-13, but not in OCI-AML2 and HL-60. BCRP and MPR3 expression was low 
in all cell lines, whereas MRP4 and MRP5 expression was from moderate to high. 
Flow cytometry studies demonstrated that MRP4, but not MRP5, was functional. The 
expression of the organic cation transporter 1 (OCT1), involved in sorafenib uptake, 
was MOLM-13>OCI-AML2≈HL-60 and non detectable in HEL and K-562. Transfection 
of HEL cells with OCT1 increased the sensitivity of these cells to sorafenib, whereas 
inactive genetic variants failed to induce this change.
Conclusion: Together with changes in the expression/function of receptors 
targeted by TKIs, the expression of plasma membrane transporters involved in 
sorafenib uptake/efflux may affect the response of leukemia cells to this drug.
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INTRODUCTION
Acute myeloid leukemia (AML) is a hematological 
neoplasm characterized by abnormal differentiation 
and increased proliferation of myeloid precursor cells, 
which accumulate in bone marrow, blood and tissues. 
A major problem in the treatment of this malignancy is 
that two-thirds of patients fail to respond to available 
chemotherapy and, in some cases, after an initial 
promising response, there is a relapse due to the 
development of drug resistance, which contributes to 
the poor long-term survival of many patients suffering 
from AML. Significant efforts are being conducted to 
develop more effective treatments as well as to identify 
biomarkers able to predict the lack of response of this 
cancer to chemotherapy.
Sorafenib is a targeted drug that has been approved 
in the USA and Europe for treating renal cell carcinoma, 
hepatocellular carcinoma and thyroid carcinoma [1–3]. 
This organic compound belongs to the family of tyrosine 
kinase inhibitors (TKIs) able to inhibit several plasma 
membrane receptors (TKRs) whose tyrosine kinase 
activity is crucial for their participation in multiple 
pathways involved in the evolution and progression of 
these malignancies.
Thus, sorafenib is able to interact with Fms-like 
tyrosine kinase 3 (FLT3) receptor, together with RAS/RAF, 
members of the platelet-derived growth factor (PDGF) 
receptor family (PDGFR and Kit) and vascular endothelial 
growth factor (VEGF) receptors 2 and 3 [4]. Of particular 
interest are the activating mutations in the FLT3 gene, 
such as internal tandem duplication (FLT3-ITD) or D835-
activating point mutations (FLT3-TKD), which lead to the 
overexpression or constitutive activation of the kinase, and 
occur in about 30% of AML cases [5]. The presence of 
the FLT3/ITD mutation is associated with poor prognosis 
in AML [6, 7], but several preclinical studies and clinical 
trials support the concept that sorafenib could be effective 
for the treatment of patients with AML, especially of those 
harboring FTL3 mutations. Promising beneficial response 
rate has been obtained using this drug either administered 
alone, in combination with other chemotherapeutic agents, 
or as maintenance chemotherapy after allogeneic stem cell 
transplantation [8–14].
Unfortunately, chemoresistance constitutes a 
major limitation for the successful treatment of AML 
with sorafenib. The mechanisms accounting for the lack 
of response to this drug are not completely understood. 
The transportome, defined as the plasma membrane 
transporters expressed at any given moment, is involved in 
the uptake and efflux of drugs, and hence accounts for the 
amount of active drug that reaches its intracellular targets 
(for a review see [15]). The organic cation transporter-1 
(OCT1, gene symbol SLC22A1) plays a major role in the 
uptake of sorafenib [16] and, at least in solid tumors, a 
decrease in the expression of this transporter and the 
presence of inactivating mutations are frequent [16]. 
Among other mechanisms of chemoresistance, changes in 
the transportome, such as overexpression of several export 
pumps, belonging to the superfamily of ATP binding 
cassette (ABC) proteins, and down-regulation of uptake 
transporters together with the presence of polymorphisms 
with loss of function, have been associated with the 
reduced sensitivity to sorafenib in different types of cancer 
[17–20].
The aim of the present study was to investigate the 
role of the transportome of AML lines in their differential 
sensitivity to sorafenib.
RESULTS
Sensitivity of leukemic cells to sorafenib
The cytostatic effect of sorafenib was determined 
in a panel of five human cell lines; four AML -OCI-
AML2, HL-60, MOLM-13 and HEL- and one derived 
from chronic myeloid leukemia (K-562). Information 
regarding subtypes of AML classification according to 
the French-American-British (FAB) cooperative group’s 
criteria and the World Health Organization (WHO) and 
typical mutations is shown in Table 1. Sorafenib induced 
a dose dependent reduction in cell viability in all these 
cell lines (Figures 1A-1E). The sensitivity to sorafenib 
was markedly higher for MOLM-13 cells than for the 
rest of cells tested. The comparison of the concentrations 
able to induce lethal effect on 50% of these cells (LC50) 
(Figure 1F) revealed that LC50 was in the μM range for 
most cell lines, except for MOLM-13, which was in the 
nM range.
Sorafenib-induced cell death was determined by 
flow cytometry. As a representative analysis, results 
obtained with HEL cells are shown in Figure 2A. Similar 
assays were carried out with the rest of the cell lines 
analyzed here (data not shown). Thus, concentration-
dependent studies indicated that sorafenib-induced cell 
death was mainly due to the enhanced activation of 
apoptosis with a minor contribution of necrosis in all cell 
lines at all concentrations assayed (Figure 2B).
Characterization of basal sorafenib-related 
transportome in leukemic cells
Basal levels of mRNA for some genes involved in 
the uptake (OCTs), the export (ABCs) and the response 
(TKRs) to sorafenib (see scheme in Figure 3A) were 
determined. Levels of SLC22A2 and SLC22A3 mRNA, 
encoding for OCT2 and OCT3, respectively, were 
undetectable in all cell lines. The expression of OCT1 
was evident in MOLM-13. The levels of SLC22A1 mRNA 
were three-fold higher in MOLM-13 than in OCI-AML2 
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Figure 1: Concentration-dependent effect of sorafenib on cell viability determined with the MTT-formazan test after exposure of MOLM-
13 (A), OCI-AML2 (B), HL-60 (C), HEL (D) and K-562 (E) cells to this drug for 72 h. Values are expressed as percentages of controls 
(cells incubated in the absence of drug). Comparison of mean LC50 in cell lines (F). Values (means±SEM) are expressed as percentages of 
controls (cells incubated in the absence of drug) from 4 experiments performed in triplicate. *, p<0.05, as compared with MOLM-13 cell 
line by the Bonferroni method of multiple comparison test.
Table 1: Characteristics of acute myeloid leukemia (AML) and K-562 cell lines
Cell line FAB WHO AML Mutations
MOLM-13 M5 monocytic leukemia sAML FLT3 ITD
OCI-AML2 M4 monocytic leukemia de novo DNMT3A
HL-60 M2 AML with maturation de novo
HEL M6 erythroid leukemia sAML JAK2
K-562 chronic myelogenous leukemia
Abbreviations: FAB, French-American-British classification system; sAML, secondary AML; WHO, World Health 
Organization classification system.
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and HL-60 cells, but were undetectable in the HEL and 
K-562 cells (Figure 3B).
Regarding export pumps, the multidrug resistance 
protein (MDR1, gene symbol ABCB1) was not detectable 
in OCI-AML2 and HL-60 cells, but was highly expressed 
in HEL>>K-562>MOLM-13 cells. Expression levels of the 
breast cancer resistance protein (BCRP, gene symbol ABCG2) 
were HEL>OCI-AML2>K-562>HL-60>MOLM-13 cells. 
Among members of the multidrug resistance-associated 
proteins (MRPs) family, several potential candidates for being 
involved in sorafenib chemoresistance were investigated. 
MRP2 (gene symbol ABCC2) was not detectable in any cell 
line (data not shown). MRP3 (gene symbol ABCC3) was not 
expressed in HL-60 and HEL cells, but ABCC3 mRNA was 
detected at low levels in OCI-AML2, MOLM-13 and K-562. 
In contrast, both MRP4 (gene symbol ABCC4) and MRP5 
(gene symbol ABCC5) were highly expressed in all five cell 
lines.
To investigate the relationship between the 
response to sorafenib and the expression of its targets, 
Figure 2: Representative images of HEL cells untreated (Control) and exposed to 10 μM sorafenib. After 72 h cells 
were incubated with Annexin V-PE in a buffer containing 7-amino-actinomycin (7-AAD) and analyzed by flow cytometry (A). A large 
population of cells was annexin V-PE and 7-AAD positive, indicating that they were in late stage apoptosis. Percentage of cell death due to 
apoptosis/necrosis in myeloid leukemia cell lines MOLM-13, OCI-AML2, HL-60, HEL and K-562 exposed to the indicated concentrations 
of sorafenib for 72 h analyzed by flow cytometry after incubation with anexin V-PE and 7-AAD (B). Values are expressed as the mean of 
three experiments performed in duplicate and SEM was always <10%.
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FLT3 and KIT mRNA levels were also determined 
(Figure 3B). In MOLM-13 cells, FLT3 expression 
was 4-fold higher than in OCI-AML2 and >4,000-
fold higher than in the rest of the cells, where 
FLT3 expression was negligible. Regarding 
KIT expression, this was HEL>OCI-AML2≈K-
562>MOLM-13>>HL-60.
Treatment-induced changes in sorafenib-related 
transportome in leukemic cells
To evaluate whether the expression profile of 
transport proteins was modified in response to the 
exposure of leukemia cells to sorafenib, the cells were 
incubated with this drug at the LC50 of each cell line for 
Figure 3: Schematic representation of sorafenib uptake transporters (organic cation transporters, OCTs), export pumps (ATP-binding 
cassette proteins, ABCs) and targets present in myeloid leukemia cells (A). Basal and sorafenib-induced mRNA expression normalized to 
GAPDH of transporters and targets of sorafenib in MOLM-13, OCI-AML2, HL-60, HEL and K-562 cells (B) determined by RT-qPCR.
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72 h. This maneuver resulted in an enhanced expression 
of several genes and the down-regulation of others 
(Figure 3B). OCT1 expression was not affected. In 
contrast, significant changes in the expression of export 
pumps associated with chemoresistance were observed, 
mainly in MOLM-13 cells, where treatment with 
sorafenib induced the up-regulation of MRP4 and MRP5. 
Regarding sorafenib molecular targets, an increase in 
FLT3 expression was observed in MOLM-13 and HL-60 
cells, while KIT expression was enhanced in MOLM-13 
and reduced in OCI-AML2 cells.
Functional studies in leukemic cells
The functionality of transporters involved in 
determining the content of sorafenib in leukemic cells 
revealed that, in general, the results were consistent 
with data regarding the expression of ABC pumps. High 
activity of MDR1 was only observed in HEL cells, as 
demonstrated by the low rhodamine-123 intracellular 
content after 30 min (Figure 4A) and the significant 
reduction of the efflux of rhodamine-123 in presence of 
verapamil (Figure 5A).
Cell load of carboxyfluorescein during the uptake 
period was lower in OCI-AML2, HL-60, HEL and K-562 
than in MOL-13 cells (Figure 4B), suggesting that MRP3-
5 activity was lower in MOLM-13 cells. No reduction of 
the efflux of the substrate was found in the presence of 
MRP3 and MRP4/5 inhibitors, p-acetamidophenyl β-D-
glucuronide (APAP-Gluc) and guanosine 3′,5′-cyclic 
monophosphate (cGMP), respectively (Figure 5B). 
These results suggested low activity of these pumps 
in all cell lines assayed. A significant reduction in 
carboxyfluorescein efflux by OCI-AML2 and HEL cells 
was observed in the presence of taurochenodeoxycholic 
acid (TCDCA) (Figure 5B), which suggested that MRP4 
was functional in these cell lines. Low activity of BCRP 
was found in all cell lines using two different substrates: 
BODIPY-prazosin (Figure 4C) and mitoxantrone (Figure 
4D). In agreement with these results no detectable effect 
of the BCRP specific inhibitor fumitremorgin C was found 
(Figure 5C and 5D).
Figure 4: Time course of cell content of fluorescent ABC substrates in myeloid leukemia cells MOLM-13, OCI-AML2, 
HL-60, HEL and K-562 during loading and efflux periods. After the cells were loaded with 1 μM rhodamine-123 (A), 1 μM 
carboxyfluorescein diacetate (B), 1 μM BODIPY-prazosin (C) or 25 μM mitoxantrone (D) at 37°C for 30 min (loading period) they were 
diluted 1:10 with substrate-free medium and incubated at 37°C for 30 min. Values (means±SEM) were determined by flow cytometry from 
3 different cultures. *, p<0.05, as compared to the substrate content after loading period.
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Finally, the functionality of OCT1 was studied 
by analyzing the ability of the cells to take up 
dihydroethidium (DHE) in an inhibitable manner. Liver 
HepG2 cells stably expressing OCT1 were used to 
test a panel of potential OCT1 inhibitors. The results 
showed that the strongest inhibitory effect was induced 
by 2-chloro-1-methylpyridinium iodide (chloro-MP) 
(Figure 6A). When chloro-MP-sensitive uptake of DHE 
was determined in all leukemia cells the following order 
was found: MOLM-13>HL-60≈OCI-AML2>HEL≈K-562 
cells (Figure 6B).
Sensitivity to sorafenib of HEL cells expressing 
OCT1
To further examine the contribution of OCT1 to the 
sensitivity of cells to sorafenib, HEL cells were selected 
because they have negligible basal expression of this 
transporter and the lowest sensitivity to sorafenib. HEL 
cells were transfected with either the wild-type or a 
mutated form of OCT1 ORF. Expression of the former, 
but not the latter, conferred HEL cells the ability to 
take up DHE (Figure 6C). Moreover, OCT1 expression 
significantly sensitized HEL cells exposed to 10 μM 
sorafenib for a short period (4 h) as compared to cells 
either transfected with an empty vector (Mock) or the 
mutated non-functional form of OCT1 (Figure 6D).
DISCUSSION
Some reports have suggested that AML cells with 
the FLT3-ITD mutation are more sensitive to sorafenib 
[8, 21]; however, a recent study has shown that FLT3 
wild-type cell lines can exhibit different sensitivities to 
this drug [22]. Also, it has been shown that the sensitivity 
of some FLT3-ITD+ cells to sorafenib can be rather poor 
[22]. In our study, MOLM-13 cells carrying the FLT3-
ITD mutation were between 250-fold and 1000-fold more 
sensitive to sorafenib than the rest of cell lines assayed. 
Moreover, differences in the sensitivity to this drug among 
the cells without this mutation were found. Thus, other 
factors, in addition to the FLT3 status, can affect the 
response to this TKI. In this and other studies [22, 23], 
cell lines reflect the heterogeneity found in response to 
drugs, which is similar to the marked variability found in 
the drug response and survival outcomes of AML patients.
In order to reach its intracellular targets, sorafenib 
needs to enter the cells by crossing the plasma membrane. 
Owing to its ionic nature in aqueous solution, which 
means high polarity, this drug cannot diffuse across the 
Figure 5: Efflux of fluorescent ABC substrates from preloaded myeloid leukemia cells MOLM-13, OCI-AML2, HL-60, 
HEL and K-562, which reflects changes in the mean fluorescence as compared with that found at the end of the loading 
period (Figure 4). After the cells were loaded with 1 μM rhodamine-123 (A), 1 μM carboxyfluorescein diacetate (B), 1 μM BODIPY-
prazosin (C) or 25 μM mitroxantrone (D) at 37°C for 30 min (loading period) they were diluted 1:10 with substrate-free medium containing, 
or not, the specific ABC inhibitors—10 μM verapamil (MDR1), 100 μM APAP glucuronide (MRP3), 100 μM taurochenodeoxycholic acid 
(TCDCA) (MRP3 and MRP4), 500 μM cGMP (MRP4 and MRP5) and 5 μM fumitremorgin C (BCRP)—and incubated at 37°C for 30 min. 
Values (means±SEM) were determined by flow cytometry from 3 different cultures. *, p<0.05, as compared to the substrate content after 
loading period.
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plasma membrane. OCT1, which mediates the facilitated 
transport of structurally different organic cations, seems 
to play a major role in its uptake [16]. Moreover, the 
presence of ABC pumps able to export sorafenib can also 
affect the amount of active drug inside the cells [17, 18, 
24]. Here we have investigated the relationship between 
the levels of uptake and efflux transporters that may 
affect the intracellular concentrations of sorafenib and the 
sensitivity of a panel of human myeloid leukemia cells.
Functional experiments using flow cytometry 
have also been carried out, since the quantification 
of mRNA levels may not always correlate with the 
amount of functional proteins due to the frequent 
presence of mutations that affect location and/or 
functionality. These studies demonstrated that, despite 
high levels of MRP5 in all the cell lines assayed here, 
this protein was not functional, because the MRP5 
inhibitor cGMP did not affect the efflux of the MRP 
substrate carboxyfluorescein. High mRNA levels of 
MDR1 were only detected in HEL cells, and functional 
experiments confirmed that only this cell line was 
able to export rhodamine 123, a typical substrate of 
this pump. Moreover, the mRNA levels of BCRP were 
low in all the cell lines, and functional studies using 
fumitremorgin C as a specific inhibitor of the substrates 
BODIPY-prazosin and mitoxantrone confirmed a 
negligible functionality of this export pump.
The fact that the HEL cell line expresses low levels 
of OCT1 and high levels of MDR1 and MRP4 was 
consistent with its low sensitivity to sorafenib. Also K-562 
cells presented extremely low levels of OCT1, a non-
functional MDR1 and moderate MRP4 activity. However, 
Figure 6: Dihydroethidium (DHE) uptake in mock HepG2 cells or stably expressing wild-type OCT1 in absence of inhibitors or in 
presence of one of the following compounds: chloro-MP, quinine, amantadine, metformine, xanthine, niacinamide, spermidine, betaine, 
dopamine (A). Chloro-MP-sensitive uptake of DHE determined by flow cytometry (B). The cells were incubated with uptake medium 
containing 5 μM DHE in the presence or absence of 100 μM chloro-MP for 30 min at 37°C before measuring fluorescence of cells. HepG2 
stably expressing OCT1 were included as positive control. Effect of the expression of wild-type OCT1 or a mutated inactive variant on 
the chloro MP-sensitive uptake of DHE in HEL cells (C). OCT1-induced sensitivity to sorafenib (D). Effect of the expression of wild-
type OCT1 or a mutated inactive variant on the viability of transfected HEL cells determined 72 hours after being incubated with 10 μM 
sorafenib for only 4 hours. Values are mean±SEM from three experiments performed in triplicate. The experiments were also carried out in 
non-transfected cells (Mock). Values are mean±SEM from two experiments performed in triplicate. *, p<0.05, as compared with the HepG2 
cells stably expressing OCT1; †, p<0.05, as compared with MOLM-13 cells; #, p<0.05, as compared with non-transfected cells (Mock); ‡, 
p<0.05, as compared with cells not treated with sorafenib (Control).
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the levels of molecular targets FLT3 and KIT were lower 
in K-562 than in HEL cells, which could contribute to the 
poor sensitivity to sorafenib.
Regarding OCT1, only MOLM-13 and, to a lesser 
degree HL-60 and OCI-AML2 cells showed a significant 
OCT1-mediated uptake of sorafenib. The presence of 
FLT3-ITD mutation together with much higher expression 
levels of this molecular target in MOLM-13 could account 
for the marked sensitivity of this cell line. The fact that 
OCI-AML2 has higher levels of FLT3 than the rest of cell 
lines FLT3-ITD- can help to explain its superior sensitivity 
to sorafenib.
From these in vitro studies we can conclude that 
functional OCT1 expression is important in AML cell 
response to sorafenib. Low expression of OCT1 is frequent 
in solid tumors [16] and also in blasts of AML patients in 
comparison to healthy individuals [25]. These findings 
have clinical implications because the identification of the 
mechanisms involved in the chemoresistance to sorafenib 
can be useful to identify patients with scarce probability of 
responding to this treatment, and also to seek therapeutic 
strategies to enhance the efficacy of this chemotherapy. In 
support of this view it should be mentioned that, recently, 
the presence of OCT1 at the plasma membrane has been 
associated with better outcome of patients with advanced 
hepatocellular carcinoma treated with sorafenib [26]. The 
results from this in vitro study further support the need of 
carrying out clinical investigations to elucidate whether 
there is an association between the clinical response 
to sorafenib and the expression of functional transport 
proteins involved in sorafenib uptake and efflux in blasts 
of patients with AML.
MATERIALS AND METHODS
Chemicals
APAP-Gluc, carboxyfluorescein diacetate, cGMP, 
chloro-MP, DHE, fumitremorgin C, mitoxantrone, 
probenecid, rhodamine 123, taurochenodeoxycholic acid 
(TCDCA), thiazolyl blue tetrazolium bromide (MTT), and 
verapamil were obtained from Sigma-Aldrich Quimica 
(Madrid, Spain). BODIPY-prazosin was from Thermo Fisher 
and sorafenib tosylate from Santa Cruz Biotechnologies.
Cell lines
Human cell lines HL-60, MOLM-13, HEL, OCI-
AML2, derived from AML, and K-562 derived from 
chronic myelogenous leukemia in blast phase (CML-
BP), were purchased from the DSMZ or ATCC cell line 
repositories and were grown in RPMI medium with 
10% heat-inactivated fetal bovine serum (FBS), except 
OCI-AML2 cells in alpha-MEM medium and 20% FBS, 
supplemented with 100 U/ml penicillin and 100 μg/ml 
streptomycin, at 37°C and 5% CO2. All cell lines were 
routinely tested to ensure they were free of mycoplasm 
contamination (Mycoplasm Gel Form Kit, Biotools, 
Madrid, Spain).
Cell viability assays
Cell viability was determined using MTT [27]. 
Briefly, cells were seeded in 96-well plates (5,000 
or 10,000 cells per well) and exposed to increasing 
concentrations of sorafenib. Drug concentrations and 
controls (untreated cells) were set up 3-fold. After 72 h, 
MTT was added to each well and microplates maintained 
at 37°C with 5% CO2 for 4 h. The amount of MTT 
reduced to formazan is proportional to living cells. The 
purple formazan crystals were solubilized in 100 μl of 
10% SDS in HCl 0.01 M and the absorbance measured 
in a microplate reader at 570 nm. The drug concentration 
required to reduce cell viability by 50% (LC50) was 
calculated from the dose-response curves.
Apoptosis was detected using the annexinV-
PE/7 amino-actinomycin (7-AAD) apoptosis detection 
kit from BD Pharmigen. Cells were seeded in 48-well 
plates (250,000 cells per well) and exposed to increasing 
concentrations of sorafenib. After 72 h, cells were 
washed and resuspended in binding buffer (1:10 diluted 
in phosphate-buffered saline). Annexin V-PE (5 μl) and 
7-AAD (5 μl) were added for 15 min. For every condition 
50,000 events were collected and analyzed. Paint-A-Gate 
Pro software (BD) was used for the analyses.
OCT1-induced sensitivity to sorafenib was studied 
in HEL cells transiently transfected with plasmids 
containing the ORF of wild-type OCT1 or an inactive 
mutated form (c.181delCGinsT) [16] with Lipofectamine 
LTX/PLUS reagent (Thermo Fisher). Two days after 
transfection, cells were incubated with 10 μM sorafenib 
for a short period of 4 hours, fresh culture medium without 
sorafenib was then used to replace drug-containing 
medium and cell viability was determined by the MTT test 
68 h later. The results were compared with those obtained 
in non-transfected HEL cells.
RT-qPCR
Total RNA extraction was carried out using the 
illustra RNAspin Mini RNA Isolation Kit (GE Healthcare 
Life Sciences, Barcelona, Spain), RNA concentration 
was determined using a Nanodrop Spectrophotometer 
(ThermoScientific) and retrotranscription was performed 
using a high-capacity cDNA reverse transcription kit 
(Applied Biosystems, Madrid). Real-time quantitative 
PCR (qPCR) was performed using AmpliTaq Gold 
polymerase (Applied Biosystems) in an ABI Prism 
7300 Sequence Detection System (Applied Biosystems) 
with the following thermal conditions: 1 cycle of 95°C 
for 10 min and 40 cycles of 95°C for 15 s and 60°C for 
60 s. The primer oligonucleotide sequences to carry 
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out qPCR are shown in Supplementary Table 1. At 
the end of each reaction, a melting curve analysis was 
performed. The 2−ΔΔCt method was applied to analyze 
the relative expression of each gene and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), which was used 
as the reference gene. For each cell line, the analysis was 
performed in cDNA obtained from two independent cell 
cultures and quantification was performed in duplicates.
Functional studies
Carboxyfluorescein, rhodamine-123 and BODIPY-
prazosin or mitoxantrone efflux assays were carried out to 
evaluate the functional activity of MRP, MDR1 and BCRP 
pumps, respectively, by flow cytometry. DHE uptake was 
determined to evaluate OCT1 functionality. Briefly, cells 
were incubated in 100 μl of uptake medium (96 mM NaCl, 
5.3 mM KCl, 1.1 mM KH2PO4, 0.8 mM MgSO4, 1.8 mM 
CaCl2, 11 mM glucose, and 50 mM HEPES, pH 7.40) 
containing 1 μM carboxyfluorescein, rhodamine-123 or 
BODIPY-prazosin or 25 μM mitoxantrone at 37°C for the 
indicated time periods. In some experiments, probenecid, 
a typical MRP inhibitor, verapamil, a typical MDR1 
inhibitor, or fumitremorgin C, a typical BCRP inhibitor, or 
other more specific MRP inhibitors (Supplementary Table 
2) were added together with the appropriate substrate. 
Then, 900 μl of ice-cold uptake medium was added to 
stop the transport process, and intracellular fluorescence 
was determined immediately by flow cytometry. Uptake 
studies were performed, as previously reported [28], using 
DHE as OCT1 substrate and 2-chloro-MP as inhibitor, 
after selecting the latter as the best inhibitor. Chloro MP-
sensitive uptake of DHE uptake was also measured in 
HEL cells transiently transfected with wild-type OCT1 or 
a mutated form of OCT1. HepG2 cells stably expressing 
OCT1 were used as a positive control. Uptake and efflux 
times were chosen based on previous studies of time-
course that are routinely performed to fix the conditions.
Statistical analysis
Data are presented as means±SEM. Paired or 
unpaired Student t-tests, as appropriate, or the Bonferroni 
method of multiple comparison test, were used to calculate 
the statistical significance of differences among groups.
Abbreviations
AML, acute myeloid leukemia; BCRP, breast 
cancer resistance protein; FLT3, Fms-like tyrosine kinase 
3; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
MDR1, multidrug resistance protein; MRP, multidrug 
resistance-associated protein; OATP, organic anion-
transporting polypeptide; OCT, organic cation transporter; 
TKR, tyrosine kinase receptor.
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